Cargando…

Age as a moderating factor of treatment resistance in depression

BACKGROUND: Treatment-resistant depression (TRD) is an important clinical challenge and may present differently between age groups. METHODS: A total of 893 depressed patients recruited within the framework of the European research consortium “Group for the Studies of Resistant Depression” were asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kautzky, Alexander, Bartova, Lucie, Fugger, Gernot, Dold, Markus, Souery, Daniel, Montgomery, Stuart, Zohar, Joseph, Mendlewicz, Julien, Fabbri, Chiara, Serretti, Alessandro, Rujescu, Dan, Kasper, Siegfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228354/ https://www.ncbi.nlm.nih.gov/pubmed/37078509 http://dx.doi.org/10.1192/j.eurpsy.2023.17

Ejemplares similares

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
por: Fugger, Gernot, et al.
Publicado: (2022)

Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression
por: Fugger, Gernot, et al.
Publicado: (2020)

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)
por: Dold, Markus, et al.
Publicado: (2018)

PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)

Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression
por: Bartova, Lucie, et al.
Publicado: (2021)

The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives
por: Fabbri, Chiara, et al.
Publicado: (2018)

Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder
por: Bartova, L., et al.
Publicado: (2022)

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
por: Dold, M., et al.
Publicado: (2018)

Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study
por: Kautzky, A., et al.
Publicado: (2018)

Silexan for treatment of anxiety and depression in the context of COVID-19
por: Bartova, Lucie, et al.
Publicado: (2023)

A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping
por: Fabbri, Chiara, et al.
Publicado: (2020)

PS87. An update on prediction of treatment outcome in treatment resistant depression
por: Kautzky, Alexander, et al.
Publicado: (2016)

Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database
por: Kraus, Christoph, et al.
Publicado: (2023)

Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation
por: Fanelli, Giuseppe, et al.
Publicado: (2022)

Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample
por: Zaninotto, Leonardo, et al.
Publicado: (2015)

The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study
por: Schosser, Alexandra, et al.
Publicado: (2017)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Silexan for treatment of psychiatric manifestations in the context of COVID-19: a case series
por: Bartova, L., et al.
Publicado: (2023)

Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited
por: Bartova, Lucie, et al.
Publicado: (2022)

Combining machine learning algorithms for prediction of antidepressant treatment response
por: Kautzky, Alexander, et al.
Publicado: (2020)

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment
por: Fabbri, Chiara, et al.
Publicado: (2020)

Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials
por: Dold, Markus, et al.
Publicado: (2023)

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
por: Fabbri, Chiara, et al.
Publicado: (2020)

Case report: Hyperactive delirium after a single dose of zolpidem administered additionally to psychopharmacotherapy including clozapine
por: Preiss, Maximilian, et al.
Publicado: (2023)

Pharmacogenetics and Depression: A Critical Perspective
por: Corponi, Filippo, et al.
Publicado: (2019)

How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach
por: Fabbri, Chiara, et al.
Publicado: (2020)

Possible Modulatory Role of ARC Gene Variants in Mood Disorders
por: Crisafulli, Concetta, et al.
Publicado: (2021)

Case report: Interstitial pneumonitis after initiation of lamotrigine
por: Watzal, Victoria, et al.
Publicado: (2023)

Towards achieving remission in the treatment of depression
por: Mendlewicz, Julien
Publicado: (2008)

Mechanische Schutzfixierung – Herausforderungen und Management: Fallvignetten aus der psychiatrischen Intermediate Care Station der Wiener Universitätsklinik
por: Popper, Valentin, et al.
Publicado: (2021)

Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank
por: Fabbri, Chiara, et al.
Publicado: (2023)

Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing
por: Fabbri, Chiara, et al.
Publicado: (2021)

Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression
por: Kautzky, Alexander, et al.
Publicado: (2019)

Correction: Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression
por: Kautzky, Alexander, et al.
Publicado: (2019)

Anhedonia and Depressive Disorders
por: Serretti, Alessandro
Publicado: (2023)

Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
por: Dold, Markus, et al.
Publicado: (2015)

Clinical Utility of Fluid Biomarker in Depressive Disorder
por: Serretti, Alessandro
Publicado: (2022)

Case Report: Bupropion Reduces the [(123)I]FP-CIT Binding to Striatal Dopamine Transporter
por: Milenkovic, Ivan, et al.
Publicado: (2021)

Obsessive-Compulsive, Psychotic, and Autism Dimensions Overlap in Real World: A Case Report
por: Scala, Mauro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dn9756g9vptdtcijbquj9tbbef